Monster Beverage is well positioned for sustained growth as its strongest-ever product innovation pipeline gathers momentum in the United States, according to Morgan Stanley, which has reaffirmed its overweight rating on the energy drink maker and maintained a price target of $103.
Shares in Monster Beverage rose around 0.4% to $98 in pre-market trading, outperforming a 0.2% gain in Nasdaq 100 futures.
The brokerage said products introduced since late 2025 now account for approximately 14.5% of the company’s US scanner sales, a sharp increase from virtually zero in September last year. It described the current wave of launches as the strongest innovation cycle in Monster’s history.
Morgan Stanley believes the expanded product portfolio will continue to support revenue growth in the near term while strengthening the company’s longer-term market share position.
Unlike previous product launches, which were largely centred on new flavours, the latest innovation strategy spans multiple categories. These include limited-edition beverages, shot-enhanced drinks, entirely new brands and products adapted from successful launches in European markets.
Among the products highlighted by the brokerage are the Ultra Red, White and Blue Razz limited-edition drink, Juice Monster Strawberry Lemonade, Strawberry Shots, the FLRT brand targeting younger female consumers, the relaunch of Storm, and US introductions of Lando Norris Zero Sugar and Juice Monster Bad Apple.
Morgan Stanley said the broader innovation strategy should enable Monster to attract new consumers and expand into additional sales channels, while reducing its reliance on traditional flavour extensions.
The brokerage also noted that many of the new products have the potential to be rolled out internationally, creating an additional avenue for growth. Overseas markets currently account for nearly half of Monster Beverage’s total revenue.
The firm added that recent product launches are already contributing to improved market share trends in the United States. Although it still expects modest market share erosion over the longer term, recent scanner data indicate year-on-year gains in recent weeks, suggesting the innovation pipeline could outperform current market expectations.
Morgan Stanley also maintained earnings forecasts above Wall Street consensus estimates through 2028, citing resilient global demand for energy drinks, continued international market share gains, an expected recovery in margins in 2027 and further operational improvements under the company’s long-term strategy.
